Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.

Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...

Cassava Sciences (SAVA) stock faces uncertainty after a major late-stage trial setback for the company's Alzheimer's candiate ...

Fintel reports that on November 26, 2024, HC Wainwright & Co. downgraded their outlook for Cassava Sciences (NasdaqCM:SAVA) from Buy to Neutral. Analyst Price Forecast Suggests 2,654.83% Upside As of ...

AM ETAUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: SAVA), a clinical-stage biotechnology company focused on ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

H.C. Wainwright analyst Vernon Bernardino downgraded Cassava Sciences (SAVA) to Neutral from Buy without a price target after the company announced results from its ReThink-ALZ Phase 3 trial with ...

Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing. Billionaire Ken ...

Wall Street witnessed a historic day with the S&P 500 and Dow Jones Industrial Average reaching record highs. The Russell ...

Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...

Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with ...